EDIT Editas Medicine, Inc. - Common Stock
$3,19
Prezzo · Ago 19, 2026
Fondamentali al Ago 5, 2026
Intervallo 52 sett.
$2–$5
53% of range
Rating Analisti
BUY
18 analysts
Prezzo Obiettivo
$6
+88% upside
P/E (TTM)
-1.8
ROE
-688.8%
Margine di Profitto Netto
-395.0%
Informazioni su Editas Medicine, Inc. - Common Stock Panoramica della società da Wikipedia
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Leggi di più
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
EDIT Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$3.19
Capitalizzazione di Mercato
$312M
P/E (TTM)
-1.8
EPS (TTM)
$-1.80
Ricavi (TTM)
$41M
Rendimento div.
—
ROE
-688.8%
D/E Debito/Patrimonio
2.1
Intervallo 52 sett.
$2 – $5
EDIT Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$41M
2016-12-31
→
2025-12-31
EPS
$-1.80
2019-12-31
→
2025-12-31
Flusso di cassa libero
$-166M
2016-12-31
→
2025-12-31
Margini
-395.0%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
EDIT
Mediana dei peer
P/E (TTM)
-1.8
17.4
P/S (TTM)
7.7
52.3
P/B
11.4
4.8
EV / EBITDA
-1.4
—
Price / FCF (Prezzo / FCF)
-1.9
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
EDIT
Mediana dei peer
Operating Margin (Margine Operativo)
-394.9%
—
Net Profit Margin (Margine di Profitto Netto)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
EDIT
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
2.1
—
Current Ratio (Rapporto corrente)
3.5
7.7
Quick Ratio
3.5
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
EDIT
Mediana dei peer
Revenue YoY (Ricavi YoY)
25.4%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
27.2%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
-14.9%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
EDIT
Mediana dei peer
EDIT Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
18 analisti
- Acquisto forte 4 22,2%
- Compra 8 44,4%
- Mantieni 4 22,2%
- Vendi 2 11,1%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
8 analisti · 2026-08-16
Mediana
$5.00
Ora
$3.19
Basso
$1.00
Alto
$15.00
Target mediano
$5.00
+57,0%
Target medio
$6.00
+88,4%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.03%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 Marzo 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 Dicembre 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 Settembre 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 Giugno 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 Marzo 2025 | $-0.92 | $-0.60 | -0.32% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 13
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Stato Patrimoniale 24
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Flusso di cassa 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Redditività 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efficienza 2
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Conto Economico 12
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Stato Patrimoniale 24
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Flusso di cassa 10
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Redditività 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efficienza 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Valutazione (TTM) 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $41M | $32M | $78M | $20M | $26M |
| Margine Operativo % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Utile netto | $-160M | $-237M | $-153M | $-220M | $-193M |
| EPS Diluito | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 2.1 | 0.4 | — | — | — |
| Rapporto corrente | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-166M | $-219M | $-137M | $-181M | $-172M |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 239 filer · $327.2M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 41 (+2 vs trimestre precedente) | 22 (-4 vs trimestre precedente) | 76 (+20 vs trimestre precedente) | 42 (-9 vs trimestre precedente) | +75.4M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 11,00% | Azioni |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 8,80% | Azioni |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 8,80% | Azioni |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 8,80% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 6,08% | Azioni |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 5,53% | Azioni |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,82% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 3,56% | Azioni |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 3,52% | Azioni |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 3,52% | Azioni |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 3,10% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 2,45% | Azioni |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 2,20% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $7.134.030 | 2.201.290 | 2,18% | Azioni |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 2,17% | Azioni |
| GOLDMAN SACHS GROUP INC | $6.763.843 | 2.087.606 | 2,07% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,32% | Azioni |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,32% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $4.201.156 | 1.296.653 | 1,28% | Azioni |
| MARSHALL WACE, LLP | $4.044.048 | 1.248.163 | 1,24% | Azioni |
| D. E. Shaw & Co., Inc. | $3.715.178 | 1.146.660 | 1,14% | Azioni |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 1,02% | Azioni |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,87% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,86% | Azioni |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,84% | Azioni |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,77% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,74% | Azioni |
| BlackRock, Inc. | $1.813.920 | 559.852 | 0,55% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,49% | Azioni |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,47% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,46% | Opzione Call |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,45% | Azioni |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,44% | Azioni |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,41% | Azioni |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,40% | Opzione Call |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,32% | Azioni |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,30% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,27% | Azioni |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,23% | Azioni |
| LPL Financial LLC | $748.813 | 231.115 | 0,23% | Azioni |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,22% | Azioni |
| IEQ CAPITAL, LLC | $705.623 | 217.785 | 0,22% | Azioni |
| Walleye Capital LLC | $595.703 | 183.859 | 0,18% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558.900 | 172.500 | 0,17% | Opzione Put |
| CITADEL ADVISORS LLC | $557.604 | 172.100 | 0,17% | Opzione Put |
| DAFNA Capital Management LLC | $552.323 | 170.470 | 0,17% | Azioni |
| Mariner, LLC | $548.500 | 169.291 | 0,17% | Azioni |
| Green Alpha Advisors, LLC | $505.589 | 156.046 | 0,15% | Azioni |
| PEAK6 LLC | $497.340 | 153.500 | 0,15% | Opzione Call |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490.555 | 151.406 | 0,15% | Azioni |
| BARCLAYS PLC | $476.030 | 146.923 | 0,15% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $464.187 | 187.930 | 0,14% | Azioni |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445.030 | 137.355 | 0,14% | Azioni |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408.240 | 126.000 | 0,12% | Azioni |
| Point72 Asset Management, L.P. | $405.758 | 125.234 | 0,12% | Azioni |
| RHUMBLINE ADVISERS | $380.421 | 117.417 | 0,12% | Azioni |
| JPMORGAN CHASE & CO | $376.528 | 117.665 | 0,12% | Azioni |
| JANE STREET GROUP, LLC | $374.473 | 115.578 | 0,11% | Azioni |
| FMR LLC | $348.384 | 107.526 | 0,11% | Azioni |
| HSBC HOLDINGS PLC | $314.481 | 97.062 | 0,10% | Azioni |
| Bank of New York Mellon Corp | $309.378 | 95.487 | 0,09% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $303.462 | 93.661 | 0,09% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300.818 | 92.845 | 0,09% | Azioni |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300.226 | 92.094 | 0,09% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $300.011 | 92.596 | 0,09% | Azioni |
| CWM, LLC | $259.352 | 105.001 | 0,08% | Azioni |
| MORGAN STANLEY | $237.324 | 73.248 | 0,07% | Azioni |
| CITADEL ADVISORS LLC | $229.392 | 70.800 | 0,07% | Opzione Call |
| OSAIC HOLDINGS, INC. | $222.928 | 68.806 | 0,07% | Azioni |
| SEI INVESTMENTS CO | $221.188 | 68.268 | 0,07% | Azioni |
| Nuveen, LLC | $221.188 | 68.268 | 0,07% | Azioni |
| Joel Isaacson & Co., LLC | $220.787 | 68.144 | 0,07% | Azioni |
| JANE STREET GROUP, LLC | $218.376 | 67.400 | 0,07% | Opzione Put |
| SIMPLEX TRADING, LLC | $207.275 | 63.974 | 0,06% | Azioni |
| MetLife Investment Management, LLC | $182.140 | 56.216 | 0,06% | Azioni |
| CITIGROUP INC | $182.052 | 56.189 | 0,06% | Azioni |
| CITADEL ADVISORS LLC | $173.923 | 53.680 | 0,05% | Azioni |
| MML INVESTORS SERVICES, LLC | $168.765 | 52.088 | 0,05% | Azioni |
| GROUP ONE TRADING LLC | $163.131 | 50.349 | 0,05% | Azioni |
| Creative Planning | $147.653 | 45.572 | 0,05% | Azioni |
| China Universal Asset Management Co., Ltd. | $143.934 | 44.424 | 0,04% | Azioni |
| WINTON GROUP Ltd | $141.588 | 43.700 | 0,04% | Azioni |
| Vanguard Global Advisers, LLC | $138.876 | 42.863 | 0,04% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $137.376 | 42.400 | 0,04% | Azioni |
| Graham Capital Management, L.P. | $134.369 | 41.472 | 0,04% | Azioni |
| Quinn Opportunity Partners LLC | $129.600 | 40.000 | 0,04% | Azioni |
| Invesco Ltd. | $128.178 | 39.561 | 0,04% | Azioni |
| Vanguard Personalized Indexing Management, LLC | $124.108 | 38.305 | 0,04% | Azioni |
| MERCER GLOBAL ADVISORS INC /ADV | $121.967 | 37.644 | 0,04% | Azioni |
| Balyasny Asset Management L.P. | $121.947 | 37.638 | 0,04% | Azioni |
| AXQ CAPITAL, LP | $118.104 | 36.452 | 0,04% | Azioni |
| Nuveen Asset Management, LLC | $113.934 | 89.712 | 0,03% | Azioni |
| SCS Capital Management LLC | $113.400 | 35.000 | 0,03% | Azioni |
| Police & Firemen's Retirement System of New Jersey | $109.749 | 33.873 | 0,03% | Azioni |
| Thrive Wealth Management, LLC | $108.540 | 33.500 | 0,03% | Azioni |
| TWO SIGMA SECURITIES, LLC | $107.367 | 33.138 | 0,03% | Azioni |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102.359 | 31.207 | 0,03% | Azioni |
| CAPTRUST FINANCIAL ADVISORS | $98.159 | 30.296 | 0,03% | Azioni |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89.683 | 27.680 | 0,03% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88.339 | 27.265 | 0,03% | Azioni |
Insider aziendali 32 insider · 13 dirigenti · 15 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 03 Giugno 2026 S | 248.313 | 0 | 1 | $-41.543 |
| MULLEN JAMES C | CEO | 03 Gennaio 2022 S | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 09 Febbraio 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 08 Gennaio 2019 S | 1.204.966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 Gennaio 2022 S | 31.462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 04 Febbraio 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 Luglio 2026 S | 62.369 | 0 | 2 | $-15.133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 Dicembre 2021 A | 31.498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 Dicembre 2021 A | 22.675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 Dicembre 2021 A | 41.785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 Ottobre 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 Marzo 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 07 Febbraio 2018 A | 4.000 | 0 | 0 | $0 |
| Elliott M. Levy | Direttore | 17 Giugno 2026 A | — | 0 | 0 | $0 |
| David Scadden | Direttore | 17 Giugno 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Direttore | 17 Giugno 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Direttore | 17 Giugno 2026 A | 22.700 | 0 | 0 | $0 |
| Andrew Hirsch | Direttore | 17 Giugno 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Direttore | 03 Settembre 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Direttore | 03 Giugno 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Direttore | 15 Giugno 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Direttore | 17 Agosto 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Direttore | 15 Giugno 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Direttore | 15 Giugno 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Direttore | 15 Giugno 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | Proprietario del 10% | 06 Settembre 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Proprietario del 10% | 08 Febbraio 2016 C | 2.649.572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 06 Agosto 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 03 Agosto 2026 S | 14.292 | 0 | 2 | $-3.002 |
| Akshay Vaishnaw | — | 03 Giugno 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 Dicembre 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 Marzo 2017 M | 117.788 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 depositi | 18 Settembre 2017 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 28 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32.319 SH | 08 Agosto 2026 | Giornaliero |
| GNOM · Global X Funds | 0,34% | 54.725 NS | 31 Maggio 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341.978 SH | 08 Agosto 2026 | Giornaliero |
| IBB · iShares Trust | 0,03% | 1.035.067 SH | 08 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8.268 SH | 08 Agosto 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 08 Agosto 2026 | Giornaliero |
| BIB · ProShares Trust | 0,02% | 3.611 NS | 31 Maggio 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1.527 NS | 31 Maggio 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823.535 SH | 08 Agosto 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118.938 SH | 08 Agosto 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,01% | 2.583.050 SH | 08 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,01% | 42.610 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4.633 NS | 31 Maggio 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476.309 NS | 31 Maggio 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3.622 NS | 31 Maggio 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32.379 NS | 31 Maggio 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3.660 NS | 31 Maggio 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120.119 SH | 08 Agosto 2026 | Giornaliero |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 Maggio 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2.922 NS | 31 Maggio 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96.350 NS | 31 Maggio 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.020 SH | 08 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 08 Agosto 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 08 Agosto 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 08 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 08 Agosto 2026 | Giornaliero |